Literature DB >> 1480747

Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease.

M Mirmiran1, D F Swaab, J H Kok, M A Hofman, W Witting, W A Van Gool.   

Abstract

Circadian rhythms are already present in the fetus. At a certain stage of pre-natal hypothalamic development (around 30 weeks of gestation) the fetus becomes responsive to maternal circadian signals. Moreover, recent studies showed that the fetal biological clock is able to generate circadian rhythms, as exemplified by the rhythms of body temperature and heart rate of pre-term babies in the absence of maternal or environmental entrainment factors. Pre-term babies that are deprived of maternal entrainment and kept under constant environmental conditions (e.g., continuous light) in the neonatal intensive care unit run the risk of developing a biological clock dysfunctioning. However, the fact should be acknowledged that at least in mice the development of the circadian pacemaker (i.e., SCN) does not depend on environmental influences (Davis and Menaker, 1981), although other data suggest that severe disruption of the maternal circadian rhythm indeed abolishes the circadian rhythm of the fetal SCN (Shibata and Moore, 1988). During aging and in particular in AD circadian rhythms are disturbed. These disturbances include phase advance and reduced period and amplitude, as well as an increased intradaily variability and a decreased interdaily stability of the rhythm. Among the factors underlying these changes the loss of SCN neurons seems to play a central role. Other contributory factors may be reduced amount of light, degenerative changes in the visual system and the level of activity and decreased melatonin.

Entities:  

Mesh:

Year:  1992        PMID: 1480747     DOI: 10.1016/s0079-6123(08)64570-7

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  13 in total

1.  Alzheimer's disease and glaucoma: imaging the biomarkers of neurodegenerative disease.

Authors:  Denise A Valenti
Journal:  Int J Alzheimers Dis       Date:  2011-01-05

Review 2.  Aging and Circadian Rhythms.

Authors:  Jeanne F Duffy; Kirsi-Marja Zitting; Evan D Chinoy
Journal:  Sleep Med Clin       Date:  2015-09-15

3.  Cytomorphometric changes in the dorsal raphe neurons after rapid eye movement sleep deprivation are mediated by noradrenalin in rats.

Authors:  Amit Ranjan; Sudipta Biswas; Birendra N Mallick
Journal:  Behav Brain Funct       Date:  2010-10-21       Impact factor: 3.759

4.  Clinical aspects of melatonin intervention in Alzheimer's disease progression.

Authors:  Daniel P Cardinali; Analía M Furio; Luis I Brusco
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

5.  Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist's viewpoint.

Authors:  J E Mintzer; D F Mirski; K S Hoernig
Journal:  Dialogues Clin Neurosci       Date:  2000-06       Impact factor: 5.986

6.  Multi-Timescale Rhythmicity of Blood Glucose and Insulin Delivery Reveals Key Advantages of Hybrid Closed Loop Therapy.

Authors:  Azure D Grant; Dana M Lewis; Lance J Kriegsfeld
Journal:  J Diabetes Sci Technol       Date:  2021-03-10

7.  Development of daily rhythmicity in heart rate and locomotor activity in the human fetus.

Authors:  Paliko I Kintraia; Medea G Zarnadze; Nicolas P Kintraia; Ia G Kashakashvili
Journal:  J Circadian Rhythms       Date:  2005-03-31

Review 8.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

9.  Locus Coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease.

Authors:  Jennifer A Ross; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2015

10.  Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin.

Authors:  Göran Hajak; Kathrin Lemme; Nava Zisapel
Journal:  Int Clin Psychopharmacol       Date:  2015-01       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.